Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero
Analysts updated ratings and price targets for several companies. Amgen (AMGN) was downgraded to market perform with a $450 target. Equifax (EFX) was upgraded to outperform with a raised target to $245. Lockheed Martin (LMT) was upgraded to buy with a target raised to $674. Other companies include Eaton (ETN), Marvell (MRVL), Sensata (ST), Synopsys (SNPS), Amphenol (APH), Cdw (CDW), Jabil (JBL), Marathon Petroleum (MPC), Phillips 66 (PSX), and Valero Energy (VLO).
How this was made
The 30-second read
Why it matters
The mix of upgrades, downgrades, and target adjustments provides fresh signals that can influence short‑term price movements, especially in pre‑market trading.
Market read
Analyst rating changes are a common catalyst for intraday moves; this roundup offers actionable intel for traders seeking to position ahead of market open.
What to watch
Underlying earnings trends and macro demand conditions are not discussed.
Background
Daily analyst recommendation roundup highlighting rating changes and target revisions for a set of North American stocks.
Ticker impact
BMO downgrades Amgen to market perform with target $450.
Modest price decline
Downgrade suggests weaker outlook; target cut may trigger sell orders.
UBS upgrades Eaton to buy, raising target to $515.
Potential upside
Upgrade and higher target may attract buyers.
BNP upgrades Equifax to outperform, target $245.
Potential upside
Higher rating and target could lift the stock.
UBS upgrades Lockheed Martin to buy, target $674.
Potential upside
Buy rating may trigger buying interest.
Guotai Haitong upgrades Marvell to overweight, target $270.20.
Potential upside
Overweight rating suggests strong outlook.
Barclays upgrades Sensata Technologies to overweight.
Potential upside
Overweight may attract institutional buying.
Morgan Stanley upgrades Synopsys to overweight, target $500.
Potential upside
Higher target may support price gains.
Barclays maintains overweight on Amphenol, cuts target to $100.
Modest decline
Lower target signals weaker expectations.
Market effects
Broad impact across healthcare, industrials, financials and energy as analysts adjust outlooks.
U.S. equities may see modest volatility in early trading.
Limited to U.S. listed companies; no direct global macro effect.
Counterpoint
Some upgrades may be premature; price targets could be overly optimistic.
Key entities
- AnalystBMO Capital Markets
Downgraded Amgen
- AnalystUBS
Provided multiple upgrades and target raises
